62nd ASH Annual Meeting and Exposition: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy

Oral and Poster Abstracts
Oral

antibodies, Biological, multiple myeloma, Animal models, Diseases, Combinations, Therapies, Biological Processes, immune cells, Technology and Procedures, immunotherapy, Plasma Cell Disorders, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, NK cells, immune mechanism, metabolomics, microenvironment, molecular interactions, proteomics

Moderators:

Karin Vanderkerken, PhD, Free University of Brussels and Eline Menu, PhD, Vrije Universiteit Brussel

Disclosures:

No relevant conflicts of interest to declare.

11:30 AM

665

Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application

Annamaria Gulla, MD¹, Eugenio Morelli, MD^2,3, Mehmet Kemal Samur, PhD⁴^*, Cirino Botta, MD, PhD⁵, Teru Hideshima, MD, PhD⁶, Giada Bianchi, MD^3,7,8, Mariateresa Fulciniti, PhD⁹, Stefano Malvestiti, MD¹⁰^*, Rao Prabhala^9,11, Srikanth Talluri, PhD^12,13^*, Yu-Tzu Tai, PhD¹⁴, Kenneth Wen¹⁵^*, Paul G. Richardson, MD^12,16, Ruben D. Carrasco, MD, PhD^3,17,18^*, Dharminder Chauhan, PhD¹⁹, Nikhil C. Munshi, MD^3,4,11 and Kenneth Anderson, MD^20,21

¹Dana Farber Cancer Institute, Boston, MA
²Department of Medical Oncology, DANA FARBER CANCER INSTITUTE, Boston, MA
³Harvard Medical School, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy
⁶Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁸Division of hematology, Brigham and Women's Hospital, Boston
⁹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁰Department of Pediatric Hematology and Oncology, Freiburg University Hospital, Freiburg, Germany
¹¹Boston VA Healthcare System, West Roxbury, MA
¹²Dana-Farber Cancer Institute, Boston, MA
¹³VA Boston Healthcare System, Boston, MA
¹⁴Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
¹⁵Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
¹⁶Medical Oncology, Harvard Medical School, Boston, MA
¹⁷Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA
¹⁸Dept. of Pathology, Brigham and Women's Hospital, Boston, MA
¹⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁰LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²¹Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

11:45 AM

666

Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma

Christie P.M. Verkleij, MD¹^*, Marloes Broekmans¹^*, Amy Wong²^*, Sonja Zweegman, MD, PhD¹, Raluca Verona, PhD²^*, Homer Adams III, PhD²^*, Tuna Mutis, MD, PhD¹^* and Niels W.C.J. Van De Donk³

¹Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands
²Janssen Research & Development, Spring House, PA
³Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands

12:00 PM

667

Restoring NK Cell Activities in Multiple Myeloma with IL-15 Receptor Agonist NKTR-255

Rafael Alonso Fernández¹^*, Laetitia Pierre-Louis¹^*, Yan Xu, MD¹^*, Shidai Mu¹^*, Joaquín Martínez-López²^*, Takahiro Miyazaki³^*, Rao Prabhala¹, Kenneth Anderson, MD¹, Loui Madakamutil³^*, Nikhil C. Munshi, MD⁴ and Mariateresa Fulciniti, PhD⁵

¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Hematology, Hospital Universitario 12 de Octubre; H12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
³Nektar Therapeutics, San Francisco, CA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

12:15 PM

668

The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma

Ram Kumar Singh, PhD¹^*, Richard J. Jones, Ph.D.²^*, Fazal M. Shirazi, Ph.D.²^*, Jianxuan M. Zou, Ph.D.²^*, Hua Wang, Ph.D.²^*, Hans C. Lee, MD², Elisabet E. Manasanch, M.D.², Isere Kuiatse, Ph.D.²^*, Andreas Pahl, Ph.D.³^* and Robert Z. Orlowski, MD, PhD²

¹Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, HOUSTON, TX
²Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
³Heidelberg Pharma AG, Ladenburg, Germany

12:30 PM

669

Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model

Evan Flietner, BS¹, Zhi Wen, PhD²^*, Adhithi Rajagopalan, BS^2,3, Joshua Wiesner, BS⁴^*, Xiaona You, PhD²^*, Yun Zhou, MS²^*, Terra Lasho, PhD⁵, Mrinal M. Patnaik, MD, MBBS⁶, Demin Wang, PhD^7,8, Robert Burns, MD⁸^*, Natalie S. Callander, MD⁹, Fotis Asimakopoulos, PhD, MBBChir,¹⁰ and Jing Zhang, PhD²

¹School of Medicine and Public Health, Cellular and Molecular Pathology Program, University of Wisconsin-Madison, Madison, WI
²McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI
³Cellular and Molecular Biology Program, University of Wisconsin-Madison, Madison, WI
⁴University of Wisconsin- Madison, Madison, WI
⁵Division of Hematology, Departments of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN
⁶Division of Hematology, Mayo Clinic, Rochester, MN
⁷Department of Microbiology and Immunology, Medical College of Wisconsin, Milwaukee, WI
⁸Blood Research Institute, BloodCenter of Wisconsin, part of Versiti, Milwaukee, WI
⁹Division of Hematology/Oncology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI
¹⁰Department of Medicine, Division of Blood and Marrow Transplant, University of California San Diego & Moores Cancer Center, La Jolla, CA

12:45 PM

670

Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity

Andrej Besse¹^*, Lenka Besse¹^*, Sara C. Stolze^2,3^*, Amin Sobh, PhD⁴, Esther A. Zaal^5,6^*, Alwin J van der Ham⁷^*, Mario Ruiz⁸^*, Santosh Phuyal⁹^*, Lorina Büchler¹^*, Marc Sathianathan¹^*, Bogdan I. Florea²^*, Jan Borén¹⁰^*, Marcus Ståhlman¹⁰^*, Alex Loguinov¹¹^*, Bart Everts⁷^*, Celia R. Berkers^5,6^*, Marc Pilon⁸^*, Hesso Farhan⁹^*, Chris D. Vulpe¹¹^*, Herman S. Overkleeft²^* and Christoph Driessen, MD¹

¹Clinics for Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
²Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
³Protein Mass Spectrometry Group, Max Planck Institute for Plant Breeding Research, Cologne, Germany
⁴DEPARTMENT OF MEDICINE, University of Florida, Gainesville, FL
⁵Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands
⁶Biomolecular Mass Spectrometry and Proteomics, Bijvoet Centre for Biomolecular Research, Utrecht University, Utrecht, Netherlands
⁷Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands
⁸Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
⁹Institute of Basic Medical Sciences, Department of Molecular Medicine, University of Oslo, Oslo, Norway
¹⁰Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
¹¹Department of Physiological Sciences, University of Florida, Gainesville, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O1.6 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy